-
Je něco špatně v tomto záznamu ?
255th ENMC workshop: Muscle imaging in idiopathic inflammatory myopathies. 15th January, 16th January and 22nd January 2021 - virtual meeting and hybrid meeting on 9th and 19th September 2022 in Hoofddorp, The Netherlands
M. de Visser, P. Carlier, J. Vencovský, K. Kubínová, C. Preusse, ENMC Muscle Imaging in Idiopathic Inflammatory Myopathies workshop study group
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu konzilia
- MeSH
- biologické markery MeSH
- kosterní svaly patologie MeSH
- lidé MeSH
- magnetická rezonanční tomografie metody MeSH
- myozitida * diagnóza MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- konzilia MeSH
- Geografické názvy
- Nizozemsko MeSH
The 255th ENMC workshop on Muscle Imaging in Idiopathic Inflammatory myopathies (IIM) aimed at defining recommendations concerning the applicability of muscle imaging in IIM. The workshop comprised of clinicians, researchers and people living with myositis. We aimed to achieve consensus on the following topics: a standardized protocol for the evaluation of muscle images in various types of IIMs; the exact parameters, anatomical localizations and magnetic resonance imaging (MRI) techniques; ultrasound as assessment tool in IIM; assessment methods; the pattern of muscle involvement in IIM subtypes; the application of MRI as biomarker in follow-up studies and clinical trials, and the place of MRI in the evaluation of swallowing difficulty and cardiac manifestations. The following recommendations were formulated: In patients with suspected IIM, muscle imaging is highly recommended to be part of the initial diagnostic workup and baseline assessment. MRI is the preferred imaging modality due to its sensitivity to both oedema and fat accumulation. Ultrasound may be used for suspected IBM. Repeat imaging should be considered if patients do not respond to treatment, if there is ongoing diagnostic uncertainty or there is clinical or laboratory evidence of disease relapse. Quantitative MRI is established as a sensitive biomarker in IBM and could be included as a primary or secondary outcome measure in early phase clinical trials, or as a secondary outcome measure in late phase clinical trials. Finally, a research agenda was drawn up.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24001126
- 003
- CZ-PrNML
- 005
- 20240213094111.0
- 007
- ta
- 008
- 240109s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.nmd.2023.08.014 $2 doi
- 035 __
- $a (PubMed)37770338
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a de Visser, Marianne $u Department of Neurology, Amsterdam Neuroscience, Amsterdam University Medical Centre, Location Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: m.devisser@amsterdamumc.nl
- 245 10
- $a 255th ENMC workshop: Muscle imaging in idiopathic inflammatory myopathies. 15th January, 16th January and 22nd January 2021 - virtual meeting and hybrid meeting on 9th and 19th September 2022 in Hoofddorp, The Netherlands / $c M. de Visser, P. Carlier, J. Vencovský, K. Kubínová, C. Preusse, ENMC Muscle Imaging in Idiopathic Inflammatory Myopathies workshop study group
- 520 9_
- $a The 255th ENMC workshop on Muscle Imaging in Idiopathic Inflammatory myopathies (IIM) aimed at defining recommendations concerning the applicability of muscle imaging in IIM. The workshop comprised of clinicians, researchers and people living with myositis. We aimed to achieve consensus on the following topics: a standardized protocol for the evaluation of muscle images in various types of IIMs; the exact parameters, anatomical localizations and magnetic resonance imaging (MRI) techniques; ultrasound as assessment tool in IIM; assessment methods; the pattern of muscle involvement in IIM subtypes; the application of MRI as biomarker in follow-up studies and clinical trials, and the place of MRI in the evaluation of swallowing difficulty and cardiac manifestations. The following recommendations were formulated: In patients with suspected IIM, muscle imaging is highly recommended to be part of the initial diagnostic workup and baseline assessment. MRI is the preferred imaging modality due to its sensitivity to both oedema and fat accumulation. Ultrasound may be used for suspected IBM. Repeat imaging should be considered if patients do not respond to treatment, if there is ongoing diagnostic uncertainty or there is clinical or laboratory evidence of disease relapse. Quantitative MRI is established as a sensitive biomarker in IBM and could be included as a primary or secondary outcome measure in early phase clinical trials, or as a secondary outcome measure in late phase clinical trials. Finally, a research agenda was drawn up.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a myozitida $x diagnóza $7 D009220
- 650 _2
- $a kosterní svaly $x patologie $7 D018482
- 650 _2
- $a magnetická rezonanční tomografie $x metody $7 D008279
- 650 _2
- $a biologické markery $7 D015415
- 651 _2
- $a Nizozemsko $7 D009426
- 655 _2
- $a konzilia $7 D016429
- 700 1_
- $a Carlier, Pierre $u CEA, Orsay, Paris, France
- 700 1_
- $a Vencovský, Jiří $u Institute of Rheumatology, Department of Rheumatology, Charles University, Prague, Czech Republic
- 700 1_
- $a Kubínová, Kateřina $u Institute of Rheumatology, Department of Rheumatology, Charles University, Prague, Czech Republic
- 700 1_
- $a Preusse, Corinna $u Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health Department of Neuropathology, Berlin, Germany
- 710 2_
- $a ENMC Muscle Imaging in Idiopathic Inflammatory Myopathies workshop study group
- 773 0_
- $w MED00003492 $t Neuromuscular disorders $x 1873-2364 $g Roč. 33, č. 10 (2023), s. 800-816
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37770338 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213094108 $b ABA008
- 999 __
- $a ok $b bmc $g 2049619 $s 1210820
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 33 $c 10 $d 800-816 $e 20230903 $i 1873-2364 $m Neuromuscular disorders $n Neuromuscul Disord $x MED00003492
- LZP __
- $a Pubmed-20240109